Vertex Pharmaceuticals (VRTX) reports Q4 earnings today. Investors are eager for updates on new drug launches and growth ...

Analysts expect the Boston, Massachusetts-based company to report quarterly earnings at $4.02 per share, down from $4.20 per share in the year-ago period. Vertex Pharmaceuticals projects quarterly ...

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting results tomorrow afternoon. Here’s what to look for.

In a report released yesterday, Jessica Fye from J.P. Morgan maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), with a ...

If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...

By Rick Winterson  Vertex Pharmaceuticals is a worldwide biotechnology corporation. It was founded 35 years ago in Cambridge.  It has now established its global headquarters on Fan Pier in South ...

This was the stock's fourth consecutive day of gains.

The U.S. Food and Drug Administration has approved a new non-opioid pain medication developed by Boston-based Vertex ...

BofA analyst Tazeen Ahmad raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $540 from $522 and keeps a Buy rating on the ...

Vertex Pharmaceuticals (NASDAQ: VRTX) has long been known as the company to turn to for life-saving cystic fibrosis (CF) ...